PROCEPT BioRobotics (NASDAQ:PRCT) Downgraded by Jefferies Financial Group to “Hold”

Jefferies Financial Group downgraded shares of PROCEPT BioRobotics (NASDAQ:PRCT) from a strong-buy rating to a hold rating in a research note released on Thursday,Zacks.com reports.

Several other equities research analysts have also commented on the stock. Morgan Stanley lowered their price target on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating on the stock in a report on Tuesday, December 2nd. TD Cowen reduced their price objective on PROCEPT BioRobotics from $50.00 to $34.00 and set a “buy” rating for the company in a research note on Thursday. UBS Group assumed coverage on PROCEPT BioRobotics in a report on Friday, December 12th. They issued a “buy” rating and a $62.00 price objective for the company. Oppenheimer reaffirmed a “market perform” rating on shares of PROCEPT BioRobotics in a report on Thursday. Finally, Piper Sandler reduced their price target on PROCEPT BioRobotics from $50.00 to $28.00 and set an “overweight” rating for the company in a research report on Thursday. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $43.60.

PROCEPT BioRobotics Stock Down 15.1%

Shares of PRCT stock opened at $23.63 on Thursday. PROCEPT BioRobotics has a fifty-two week low of $19.35 and a fifty-two week high of $68.70. The firm has a market capitalization of $1.32 billion, a PE ratio of -13.82 and a beta of 0.99. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.20 and a current ratio of 8.44. The stock’s 50-day simple moving average is $30.18 and its 200-day simple moving average is $33.64.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 24.82%. The firm had revenue of $76.38 million during the quarter, compared to analysts’ expectations of $93.70 million. During the same quarter in the prior year, the company earned ($0.35) EPS. PROCEPT BioRobotics’s quarterly revenue was up 11.9% on a year-over-year basis. Equities analysts expect that PROCEPT BioRobotics will post -1.75 earnings per share for the current year.

Institutional Trading of PROCEPT BioRobotics

Institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd increased its position in shares of PROCEPT BioRobotics by 436.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after buying an additional 746 shares in the last quarter. JTC Employer Solutions Trustee Ltd acquired a new stake in PROCEPT BioRobotics in the 3rd quarter valued at $30,000. Center for Financial Planning Inc. purchased a new stake in PROCEPT BioRobotics in the 4th quarter worth $40,000. Vega Investment Solutions increased its holdings in PROCEPT BioRobotics by 52.0% in the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after acquiring an additional 265 shares in the last quarter. Finally, US Bancorp DE raised its position in PROCEPT BioRobotics by 175.7% during the third quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after acquiring an additional 1,079 shares during the period. 89.46% of the stock is owned by institutional investors and hedge funds.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Management set FY‑2026 revenue guidance of $390M–$410M, which is slightly above consensus (≈$384M) and signals the company still expects multi‑year growth despite near‑term headwinds. Article Title
• Positive Sentiment: Quarterly operating performance showed improvement vs. prior year (operating loss and net loss narrowed materially) and the company finished the quarter with substantial cash (~$286.5M), which supports near‑term liquidity. Article Title
• Neutral Sentiment: The company hosted a 2026 Investor Day to outline its multi‑year strategic plan and commercial realignment; the event provides context on how management plans to restore growth and margin leverage. Article Title
• Neutral Sentiment: Institutional activity and analyst price targets are mixed (median target ~$34) — some firms see upside after the selloff while others have lowered expectations. This creates divergent analyst signals for investors. Article Title
• Negative Sentiment: Q4 results missed expectations: EPS -$0.53 vs. consensus -$0.32 and revenue $76.4M vs. ~$93.7M est. Management also set Q1 revenue guidance ($79M–$82M) well below consensus, driving near‑term revenue concerns. Article Title
• Negative Sentiment: A law firm (Ademi LLP) announced an investigation into potential securities‑fraud claims related to the company’s disclosures, adding regulatory/legal risk and investor uncertainty. Article Title
• Negative Sentiment: Several brokers cut price targets or downgraded the stock (Jefferies to Hold, BofA to Underperform with $20 PT, Leerink cut its PT to $30, TD Cowen and Piper Sandler trimmed targets), increasing selling pressure. Article Title
• Negative Sentiment: PRCT shares hit a 52‑week low after the combination of the earnings miss, weak near‑term guidance and negative headlines. Article Title

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.